Anti-DFS antibodies occur more commonly in patients following unprovoked venous thromboembolism.
It has been reported in a small group of patients that a significant percentage of patients with anti-DFS (dense fine speckled) antibodies has a history of idiopathic arterial or venous thrombosis and/or obstetric complications. To our knowledge there have been no larger studies regarding the prevalence of anti-DFS antibodies in provoked and unprovoked venous thromboembolism (VTE). We investigated how common anti-DFS70 antibodies occur in patients following VTE and which factors affect their occurrence in this disease. We screened 287 consecutive adult patients, aged below 60 years, with documented VTE treated for at least 3 months, and 129 age-matched healthy controls. Patients with cancer, severe comorbidities, documented autoimmune diseases, including antiphospholipid syndrome were ineligible. The anti- -DFS70 antibodies were determined based on immunofluorescence on Hep-2 cells. The specific immunofluorescence pattern, characterized by dense fine speckles distributed the nucleus, observed at serum dilution equal to or greater than 1:100, was considered as positive and was confirmed using the semiquantitative ELISA-DFS that provided results as a ratio (RU/ml) with a cut-off of 1. There was no difference in the prevalence of anti-DFS70 antibodies in the VTE and control patients (n=12, 4.18% vs. n=6, 4.65%, p=0.68). Anti-DFS antibodies represented 9.16% of all positive ANA patterns (n=131) in VTE patients, which was a much lower proportion compared with 26.1% of all 23 positive ANA patterns in healthy subjects (p=0.031). The presence of anti-DFS antibodies did not correlate with demographic or clinical variables including time since last VTE event, type of anticoagulation and its quality. The prevalence of anti-DFS70 antibodies was higher in patients with ANA titer ≥1:320 compared to those with the titer < 1:320 (75% vs. 37%, p=0.01). Of importance, higher prevalence of anti-DFS antibodies was observed in patients with unprovoked VTE compared to those with provoked VTE (75% vs. 25%, p=0.01). Among the VTE patients with heritable thrombophilia, i.e. factor V Leiden or prothrombin G20210A mutations, 25.8% of subjects (n=8) had anti-DFS antibodies. Moreover, anti-DFS titer was associated with serum alpha and gamma globulin levels (r=0.47, p=0.027; and r=0.39, p=0.045, respectively), but not with inflammatory markers or D-dimer in VTE patients. Anti-DFS antibodies are present in <5% of VTE patients and are associated with unprovoked VTE including that related to heritable thrombophilia. It might suggest that these antibodies are involved in the pathogenesis of idiopathic VTE.